Bortezomib Cancer Research Results

BTZ, Bortezomib: Click to Expand ⟱
Features:
Bortezomib (often abbreviated as BTZ) is a proteasome inhibitor that has been approved for the treatment of certain types of cancers, most notably multiple myeloma and mantle cell lymphoma.
Mechanism of Action
Proteasome Inhibition:
Bortezomib targets the 26S proteasome, a complex responsible for degrading ubiquitinated proteins. By inhibiting the proteasome’s activity, bortezomib causes an accumulation of unwanted or misfolded proteins within the cell.

Induction of Apoptosis:
The buildup of these proteins leads to cellular stress and activation of the unfolded protein response (UPR). In cancer cells, which often have high levels of protein synthesis and turnover, this stress quickly tips the balance toward apoptosis (programmed cell death).

Disruption of Cell Signaling Pathways:
Proteasome inhibition affects several signaling pathways, including the nuclear factor-kappa B (NF-κB) pathway. NF-κB is a key regulator of cell survival, proliferation, and inflammation. Its inhibition contributes to decreased survival signals for cancer cells, enhancing the cytotoxic effects of the treatment.

Bortezomib — Bortezomib is a dipeptidyl boronic acid small-molecule antineoplastic that functions as a reversible proteasome inhibitor, with highest functional relevance at the chymotrypsin-like catalytic activity of the 26S proteasome. It is a conventional cytotoxic/targeted hematologic oncology drug, marketed most prominently as Velcade, and commonly abbreviated BTZ. Clinically, it is an established systemic therapy for multiple myeloma and mantle cell lymphoma, with administration by subcutaneous or intravenous route rather than oral delivery. Its therapeutic niche is strongest in proteostasis-dependent malignancies, especially plasma-cell disorders, where high secretory load and unfolded-protein stress make malignant cells particularly vulnerable to proteasome blockade.

Primary mechanisms (ranked):

  1. 26S proteasome inhibition, especially blockade of the β5 chymotrypsin-like catalytic activity, causing ubiquitinated protein accumulation and collapse of proteostasis.
  2. Endoplasmic reticulum stress and unfolded protein response overload, progressing to CHOP/caspase-linked apoptosis in proteostasis-heavy tumor cells.
  3. Disruption of pro-survival signaling and turnover of short-lived regulatory proteins, including context-dependent suppression/remodeling of NF-κB signaling and stabilization of pro-apoptotic programs.
  4. Mitochondrial injury with secondary oxidative stress, loss of membrane potential, cytochrome c release, and apoptotic amplification.
  5. Microenvironment and drug-sensitization effects, including synergy with steroids, alkylators, antibodies, and some ER-stress or redox-active combinations.
  6. Resistance biology centered on adaptive proteostasis, altered stress handling, and proteasome-subunit changes such as PSMB5-linked resistance.

Bioavailability / PK relevance: Bortezomib is not used orally in standard oncology practice because systemic delivery is by SC or IV administration. SC exposure is clinically comparable to IV for efficacy-relevant proteasome inhibition, with lower neuropathy risk. It is widely distributed, undergoes hepatic oxidative metabolism, and shows a long apparent terminal half-life after repeated dosing; hepatic impairment is more PK-relevant than renal impairment for dose adjustment.

In-vitro vs systemic exposure relevance: Many mechanistic cell-culture studies use low-nanomolar to higher-nanomolar or submicromolar concentrations; the clinically relevant range is plausible for direct proteasome inhibition, but some exaggerated ROS, mitochondrial, or combination effects in vitro may require longer exposure or higher concentrations than are uniformly sustained in patients. Because bortezomib is target-engaged at the proteasome rather than simply concentration-driven bulk exposure, pharmacodynamic proteasome inhibition is more informative than plasma concentration alone.

Clinical evidence status: Approved standard-of-care systemic anticancer drug with robust human evidence, including randomized phase III data and long-standing regulatory approval in multiple myeloma and mantle cell lymphoma. Evidence is strongest in hematologic malignancy regimens and weaker/inconsistent for solid tumors as single-agent therapy.

Mechanistic profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 26S proteasome catalytic function ↓ ↓ P-R Proteostasis blockade Core on-target effect; malignant plasma cells are especially vulnerable because of high protein synthesis and secretory burden.
2 Unfolded protein response and ER stress ↑ ↑ (usually less lethal) R-G ER-stress overload leading to apoptosis Central translation mechanism from proteasome inhibition to cell death; strong relevance in multiple myeloma.
3 Apoptosis caspase program ↑ ↑ (context-dependent) R-G Programmed cell death Includes caspase activation, pro-apoptotic BH3 shifts, and terminal execution after unresolved proteotoxic stress.
4 NF-κB survival signaling ↓ (context-dependent) ↓ (context-dependent) R-G Reduced pro-survival transcriptional support Historically important rationale, but biologic response is not uniformly simple; canonical NF-κB can be remodeled or paradoxically activated in some models.
5 Mitochondrial integrity and MPTP-related injury ↓ mitochondrial function ↓ (dose-dependent) R-G Mitochondrial apoptotic amplification Loss of membrane potential and cytochrome c release commonly reinforce killing; may be stronger in combination settings.
6 Mitochondrial ROS increase ↑ ↑ (dose-dependent) R-G Oxidative stress sensitization Usually secondary rather than primary; can contribute to apoptosis and combination synergy, but not the cleanest universal driver across all systems.
7 NRF2 redox adaptation ↔ / ↑ (context-dependent) ↑ (context-dependent) G Stress adaptation and resistance pressure More relevant to resistance and redox compensation than to first-order mechanism; not a defining therapeutic axis but mechanistically relevant in some resistant states.
8 HIF-1α ↓ (context-dependent) ↔ G Reduced hypoxia-supportive signaling Observed in some models; likely secondary and tumor-context dependent rather than universally dominant.
9 Glycolysis and lactate output ↓ / ↔ (context-dependent) ↔ G Metabolic stress remodeling Can accompany proteotoxic stress and sensitization, but this is not the main clinically leveraged axis.
10 Chemosensitization ↑ sensitivity ↔ / toxicity-limited G Combination benefit Clinically validated in combination regimens for myeloma and lymphoma; also strong preclinical sensitizer to ER-stress-active and apoptotic therapies.
11 Proteasome-subunit resistance axis ↑ resistance escape ↔ G Acquired resistance PSMB5 and broader adaptive proteostasis changes are major escape routes that constrain durability.
12 Clinical Translation Constraint Neuropathy and resistance limit exposure Peripheral nerve toxicity risk ↑ G Delivery and tolerability boundary SC dosing improves tolerability versus IV, but peripheral neuropathy, thrombocytopenia, GI toxicity, herpes zoster risk, and resistance remain major translational constraints.

P: 0–30 min
R: 30 min–3 hr
G: >3 hr
Scientific Papers found: Click to Expand⟱
4620- Bor,  BTZ,    Boron Compounds in the Breast Cancer Cells Chemoprevention and Chemotherapy
- Review, Var, NA - Review, Arthritis, NA - Review, Pca, NA
Risk↓, *memory↑, *Dose↑, Risk↓, other↝, *testos↑, other↝, Risk↓, TumCP↓, Apoptosis↑, eff↑,
5674- BTZ,    Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic, anti-tumor effects
- in-vivo, GBM, NA - in-vivo, HNSCC, NA
ER Stress↑, GRP78/BiP↑, CHOP↑, PERK↑, IRE1↑, UPR↑, HSP70/HSPA5↑, HSP90↑, eff↑,
1866- DCA,  MET,  BTZ,    Targeting metabolic pathways alleviates bortezomib-induced neuropathic pain without compromising anticancer efficacy in a sex-specific manner
- in-vivo, NA, NA
eff↑, TumCG↓, Hif1a↓, PDH↑, lactateProd↓, TumVol↓, TumW↓, Glycolysis↑, neuroP↑,
1843- dietFMD,  BTZ,    Cyclic Fasting–Mimicking Diet Plus Bortezomib and Rituximab Is an Effective Treatment for Chronic Lymphocytic Leukemia
- in-vivo, CLL, NA
AntiTum↓, Apoptosis↑, IGF-1↓, eff↑, OS↑, eff↑,
1060- LT,  BTZ,    Luteolin inhibits the TGF-β signaling pathway to overcome bortezomib resistance in multiple myeloma
- vitro+vivo, Melanoma, NA
ALDH1A1↓, TGF-β↓, ChemoSen↑,

Showing Research Papers: 1 to 5 of 5

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

Glycolysis↑, 1,   lactateProd↓, 1,   PDH↑, 1,  

Cell Death ⓘ

Apoptosis↑, 2,  

Transcription & Epigenetics ⓘ

other↝, 2,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   ER Stress↑, 1,   GRP78/BiP↑, 1,   HSP70/HSPA5↑, 1,   HSP90↑, 1,   IRE1↑, 1,   PERK↑, 1,   UPR↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

ALDH1A1↓, 1,   IGF-1↓, 1,   TumCG↓, 1,  

Migration ⓘ

TGF-β↓, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature ⓘ

Hif1a↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   eff↑, 5,  

Functional Outcomes ⓘ

AntiTum↓, 1,   neuroP↑, 1,   OS↑, 1,   Risk↓, 3,   TumVol↓, 1,   TumW↓, 1,  
Total Targets: 27

Pathway results for Effect on Normal Cells:


Hormonal & Nuclear Receptors ⓘ

testos↑, 1,  

Drug Metabolism & Resistance ⓘ

Dose↑, 1,  

Functional Outcomes ⓘ

memory↑, 1,  
Total Targets: 3

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:257  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page